Lenalidomide use in multiple myeloma (Review)
- Authors:
- Chao-Wei Zhang
- Ya-Nan Wang
- Xue-Ling Ge
-
Affiliations: Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China - Published online on: November 28, 2023 https://doi.org/10.3892/mco.2023.2705
- Article Number: 7
-
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Bird SA and Boyd K: 9. Multiple myeloma: An overview of management. Palliat Care Soc Pract. 13(1178224219868235)2019.PubMed/NCBI View Article : Google Scholar | |
|
Nijhof IS, van de Donk NWCJ, Zweegman S and Lokhorst HM: Current and new therapeutic strategies for relapsed and refractory multiple myeloma: An update. Drugs. 78:19–37. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Shah UA and Mailankody S: Emerging immunotherapies in multiple myeloma. BMJ. 370(m3176)2020.PubMed/NCBI View Article : Google Scholar | |
|
Pinto V, Bergantim R, Caires HR, Seca H, Guimarães JE and Vasconcelos MH: Multiple Myeloma: Available therapies and causes of drug resistance. Cancers (Basel). 12(407)2020.PubMed/NCBI View Article : Google Scholar | |
|
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN: Diagnosis and management of multiple myeloma: A review. JAMA. 327:464–477. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Delforge M, Vlayen S and Kint N: Immunomodulators in newly diagnosed multiple myeloma: Current and future concepts. Expert Rev Hematol. 14:365–376. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA and Alam U: Chemotherapy-Induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol Ther. 9:385–450. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Tageja N: Lenalidomide-current understanding of mechanistic properties. Anticancer Agents Med Chem. 11:315–326. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Cives M, Simone V, Brunetti O, Longo V and Silvestris F: Novel lenalidomide-based combinations for treatment of multiple myeloma. Crit Rev Oncol Hematol. 85:9–20. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Quach H, Kalff A and Spencer A: Lenalidomide in multiple myeloma: Current status and future potential. Am J Hematol. 87:1089–1095. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J and Verstovsek S: Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 118:899–902. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B and Verma A: Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2(36)2009.PubMed/NCBI View Article : Google Scholar | |
|
Tawara K, Scott H, Emathinger J, Ide A, Fox R, Greiner D, LaJoie D, Hedeen D, Nandakumar M, Oler AJ, et al: Co- Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion. Transl Oncol. 12:245–255. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Matthes T, Manfroi B and Huard B: Revisiting IL-6 antagonism in multiple myeloma. Crit Rev Oncol Hematol. 105:1–4. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhou J, Shen Q, Lin H, Hu L, Li G and Zhang X: Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment. J Cancer Res Clin Oncol. 145:329–336. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Díaz T, Rodríguez V, Lozano E, Mena MP, Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J, et al: The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica. 102:1776–1784. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kulikov AV, Shilov ES, Mufazalov IA, Gogvadze V, Nedospasov SA and Zhivotovsky B: Cytochrome c: The Achilles' heel in apoptosis. Cell Mol Life Sci. 69:1787–1797. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Li L, Hua Y, Dong M, Li Q, Smith DT, Yuan M, Jones KR and Ren J: Short-term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob/ob obese mice. Obesity (Silver Spring). 20:2174–2185. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zhou L, Huang X, Niesvizky R, Pu Z and Xu G: Caspase-8 regulates the antimyeloma activity of bortezomib and lenalidomide. J Pharmacol Exp Ther. 379:303–309. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Zhou L: Caspase-8: Friend or Foe in bortezomib/lenalidomide-based therapy for myeloma. Front Oncol. 12(861709)2022.PubMed/NCBI View Article : Google Scholar | |
|
Felici C, Passarelli A, Cafforio P, Racanelli V, Leone P and Tucci M: Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells. Melanoma Res. 33:357–363. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Wong AH, Shin EM, Tergaonkar V and Chng WJ: Targeting NF-κB signaling for multiple myeloma. Cancers (Basel). 12(2203)2020.PubMed/NCBI View Article : Google Scholar | |
|
Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, Galson DL and Lentzsch S: IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 117:5157–5165. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Bou Zerdan M, Nasr L, Kassab J, Saba L, Ghossein M, Yaghi M, Dominguez B and Chaulagain CP: Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. Int J Hematol Oncol. 11(IJH39)2022.PubMed/NCBI View Article : Google Scholar | |
|
Qu X, Mei J, Yu Z, Zhai Z, Qiao H and Dai K: Lenalidomide regulates osteocytes fate and related osteoclastogenesis via IL-1β/NF-κB/RANKL signaling. Biochem Biophys Res Commun. 501:547–555. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, et al: The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 4:4195–4207. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Castelli R, Cassin R, Cannavò A and Cugno M: Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 13:1–7. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H and Hundemer M: Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(-) T-cells. Oncotarget. 8:98200–98214. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Richardson K, Keam SP, Zhu JJ, Meyran D, D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, et al: The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. Haematologica. 108:83–97. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Bodera P and Stankiewicz W: Immunomodulatory properties of thalidomide analogs: Pomalidomide and lenalidomide, experimental and therapeutic applications. Recent Pat Endocr Metab Immune Drug Discov. 5:192–196. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, et al: The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 116:2286–2294. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Hallett WH, Jing W, Drobyski WR and Johnson BD: Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant. 17:1133–1145. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, et al: Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 27:464–472. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Chen N, Kasserra C, Reyes J, Liu L and Lau H: Single-dose pharmacokinetics of lenalidomide in healthy volunteers: Dose proportionality, food effect, and racial sensitivity. Cancer Chemother Pharmacol. 70:717–725. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Chen N, Weiss D, Reyes J, Liu L, Kasserra C, Wang X, Zhou S, Kumar G, Weiss L and Palmisano M: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers. Cancer Chemother Pharmacol. 73:1031–1039. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Chen N, Ye Y, Liu L, Reyes J, Assaf MS, Kasserra C, Zhou S and Palmisano M: Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol. 113:179–186. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Larocca A, Bonello F, Gaidano G, D'Agostino M, Offidani M, Cascavilla N, Capra A, Benevolo G, Tosi P, Galli M, et al: Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 137:3027–3036. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lund J, Gruber A, Lauri B, Duru AD, Blimark C, Swedin A, Hansson M, Forsberg K, Ahlberg L, Carlsson C, et al: Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma. Cancer Med. 7:2256–2268. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, et al: Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet. 389:519–527. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Mohammad NS, Nazli R, Zafar H and Fatima S: Effects of lipid based Multiple Micronutrients Supplement on the birth outcome of underweight pre-eclamptic women: A randomized clinical trial. Pak J Med Sci. 38:219–226. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Zou Y, Lin M, Sheng Z and Niu S: Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma. 55:2024–2031. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, Gupta VA, Boise LH, Lonial S and Nooka AK: Long-Term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 38:1928–1937. 2020.PubMed/NCBI View Article : Google Scholar | |
|
McCaughan GJ, Gandolfi S, Moore JJ and Richardson PG: Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: A practical review. Br J Haematol. 199:190–204. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, et al: Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 9:e810–e821. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, et al: Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 136:936–945. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, et al: Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 376:1311–1320. 2017.PubMed/NCBI View Article : Google Scholar | |
|
O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, et al: A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 182:222–230. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, et al: Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Cancer Sci. 109:1552–1561. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Dimopoulos MA, Laubach JP, Echeveste Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, Kumar S, Labotka R, Lu V, Berg D, et al: Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. Eur J Haematol. 102:494–503. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, et al: Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: Long-term follow-up including ixazomib maintenance. Leukemia. 33:1736–1746. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, et al: Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 137:3616–3628. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, et al: Safety and efficacy of combination maintenance therapy with ixazomib and lenalidomide in patients with posttransplant myeloma. Clin Cancer Res. 28:1277–1284. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, et al: Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 39:2430–2442. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, et al: Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. Eur J Haematol. 106:555–562. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Jakubowiak A, Usmani SZ, Krishnan A, Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM, Schecter JM and Chari A: Daratumumab plus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 21:701–710. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, et al: Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21:1317–1330. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, et al: Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 136:2513–2523. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Roussel M, Lauwers-Cances V, Wuilleme S, Belhadj K, Manier S, Garderet L, Escoffre-Barbe M, Mariette C, Benboubker L, Caillot D, et al: Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood. 138:113–121. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J and Stewart AK: Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 36:728–734. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, et al: Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. Ther Adv Hematol. 13(20406207221104584)2022.PubMed/NCBI View Article : Google Scholar | |
|
Baertsch MA, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, Müller-Tidow C, Goldschmidt H, Raab MS, Hillengass J and Giesen N: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Cancers (Basel). 13(4706)2021.PubMed/NCBI View Article : Google Scholar | |
|
Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL and Mohty M: Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An update. Blood Cancer J. 12(47)2022.PubMed/NCBI View Article : Google Scholar | |
|
Pulte ED, Dmytrijuk A, Nie L, Goldberg KB, McKee AE, Farrell AT and Pazdur R: FDA approval summary: Lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist. 23:734–739. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu J, Zhao R, Jiang X, Li Z and Zhang B: Progress on the application of bortezomib and bortezomib-based nanoformulations. Biomolecules. 12(51)2021.PubMed/NCBI View Article : Google Scholar | |
|
Yang MH, Jung SH, Chinnathambi A, Alahmadi TA, Alharbi SA, Sethi G and Ahn KS: Attenuation of STAT3 signaling cascade by daidzin can enhance the apoptotic potential of bortezomib against multiple myeloma. Biomolecules. 10(23)2019.PubMed/NCBI View Article : Google Scholar | |
|
Medhekar R, Ran T, Fu AZ, Patel S and Kaila S: Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer. 22(901)2022.PubMed/NCBI View Article : Google Scholar | |
|
Harousseau JL and Mohty M: Daratumumab in transplant regimens for myeloma? Blood. 136:917–918. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Goicoechea I, Puig N, Cedena MT, Burgos L, Cordón L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz MJ, Ramos MM, et al: Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 137:49–60. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Shirley M: Ixazomib: First global approval. Drugs. 76:405–411. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ and Kirk CJ: Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events. Clin Cancer Res. 17:2734–2743. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Jayaweera SPE, Wanigasinghe Kanakanamge SP, Rajalingam D and Silva GN: Carfilzomib: A promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Front Oncol. 11(740796)2021.PubMed/NCBI View Article : Google Scholar | |
|
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, et al: Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 20:57–73. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hamnvik OP, Larsen PR and Marqusee E: Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 103:1572–1587. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Koeppen S: Treatment of multiple myeloma: Thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy. Oncol Res Treat. 37:506–513. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Dalla Torre C, Zambello R, Cacciavillani M, Campagnolo M, Berno T, Salvalaggio A, De March E, Barilà G, Lico A, Lucchetta M, et al: Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. Neurology. 87:1161–1166. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Patrizi A, Venturi M, Dika E, Maibach H, Tacchetti P and Brandi G: Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. Cutan Ocul Toxicol. 33:1–6. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Tinsley SM, Kurtin SE and Ridgeway JA: Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 15 (Suppl):S64–S69. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Shanbhag A, Pritchard ER, Chatterjee K and Hammond DA: highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide. Hosp Pharm. 52:408–411. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R and Morgan GJ: A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 119:2764–2767. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Nojkov B, Signori C, Konda A and Fontana RJ: Lenalidomide-associated hepatotoxicity-a case report and literature review. Anticancer Res. 32:4117–4119. 2012.PubMed/NCBI | |
|
Hussain S, Browne R, Chen J and Parekh S: Lenalidomide-induced severe hepatotoxicity. Blood. 110(3814)2007.PubMed/NCBI View Article : Google Scholar | |
|
Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, et al: Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 131:301–310. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, et al: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 371:906–917. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, et al: Triplet Therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 387:132–147. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Nucci M and Anaissie E: Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 49:1211–1225. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Kikuchi T, Kusumoto S, Tanaka Y, Oshima Y, Fujinami H, Suzuki T, Totani H, Kinoshita S, Asao Y, Narita T, et al: Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy. J Clin Exp Hematop. 60:51–54. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Kekre N and Connors JM: Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 33:24–32. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, Mailankody S, Lesokhin A, Shah U, Lu S, et al: Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol. 196:105–109. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, et al: Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 136:1091–1104. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Bwire R, Freeman J and Houn F: Managing the teratogenic risk of thalidomide and lenalidomide: An industry perspective. Expert Opin Drug Saf. 10:3–8. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Somers GS: Thalidomide and congenital abnormalities. Lancet. 1:912–913. 1962.PubMed/NCBI View Article : Google Scholar | |
|
Mueller M and Lewis DJ: Implementation of a pregnancy prevention programme (PPP) with a controlled distribution system (CDS) for the generic teratogenic phthalimides thalidomide, lenalidomide and pomalidomide. Ther Innov Regul Sci. 55:1155–1164. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Hui JY, Fuchs A and Kumar G: Embryo-fetal exposure and developmental outcome of lenalidomide following oral administration to pregnant cynomolgus monkeys. Reprod Toxicol. 114:57–65. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, Ahmann JM, de Campos CB, Braggio E, Bergsagel PL and Stewart AK: Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 9(19)2019.PubMed/NCBI View Article : Google Scholar | |
|
Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, et al: Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 27:491–503. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Bukowski K, Kciuk M and Kontek R: Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 21(3233)2020.PubMed/NCBI View Article : Google Scholar | |
|
Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, Lonial S and Rajkumar SV: Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer J. 8(86)2018.PubMed/NCBI View Article : Google Scholar | |
|
Chen N, Zhou S and Palmisano M: Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 56:139–152. 2017.PubMed/NCBI View Article : Google Scholar |
